Kofi Mensah, MD, PhD
About
Biography
Dr Mensah is a graduate of the NIH medical-scientist training program (MSTP) at the University of Rochester where he received his PhD in immunology under the direction of Edward Schwarz, PhD and Christopher Ritchlin, MD. His dissertation looked at immune system regulation of osteoclastogenesis in the context of inflammatory arthritis. His research won first place out of over 1,500 submissions in the basic science research category at the 2006 American College of Physicians National Medical Student Abstract Competition. His dissertation received the Melville A. Hare Award for Distinction in Research (2009). He also had the honor of presenting his research at the American College of Rheumatology annual meeting,the American Society for Clinical Investigation annual meeting, the American Society for Bone and Mineral Research annual meeting and the American Academy of Orthopaedic Surgeons annual meeting. He is the co-inventor of a novel monoclonal antibody patented for use in the identification of osteoclast precursors. He has also done research under the mentorship of John Mudgett, PhD at Merck Research Laboratories, Steven Teitelbaum, MD and F. Patrick Ross, PhD at Washington University in St Louis, as well as Steven Goldring, MD, Edward Purdue, PhD, Lionel Ivashkiv, MD, and Joseph Lane, MD at Hospital for Special Surgery. Dr Mensah is a member of the Alpha Omega Alpha and Phi Beta Kappa honor societies. He has mentored high school, undergraduate, graduate and medical students. As part of his mentorship role, he has served as a judge for the New York City Science and Engineering Fair and the New England Science Symposium. He has also lectured for medical students and residents on the topic of immunology and musculoskeletal medicine topics. He received the Robert Leet Patterson and Clara Guthrie Patterson Trust Mentored Research Award to fund post-doctoral research with Eric Meffre, PhD on pathogenic roles of B cells in rheumatoid arthritis. He served on the Executive Council for the Yale Internal Medicine Residency Program and is on the Board of Directors of the American Physician Scientists Association.
Appointments
Rheumatology
Assistant Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Residency
- Yale University (2015)
- Residency
- Hospital for Special Surgery/Weill Cornell (2013)
- MD
- University of Rochester School of Medicine and Dentistry (2011)
- PhD
- University of Rochester School of Medicine and Dentistry (2009)
Board Certifications
Rheumatology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2016
Research
Overview
Medical Research Interests
ORCID
0000-0001-8737-3130
Research at a Glance
Yale Co-Authors
Publications Timeline
Abhijeet Danve, MBBS, MD, MHS
Gilbert Moeckel, MD, PhD, FASN
Jonathan Leventhal, MD
Publications
2023
Health service delivery factors influencing neonatal mortality in health facilities in the bono region of Ghana
Brobbey R, Kwawukume M, Twum P, Agyei-Baffour P, Opoku D, Antwi-Berko N, Vetsi O, Apara J, Mensah K. Health service delivery factors influencing neonatal mortality in health facilities in the bono region of Ghana. World Journal Of Advanced Research And Reviews 2023, 17: 157-176. DOI: 10.30574/wjarr.2023.17.3.0368.Peer-Reviewed Original Research
2018
Granulomatosis With Polyangiitis in a Young Adult With Down Syndrome
Mensah KA, Pascha V, Moeckel G, Danve A. Granulomatosis With Polyangiitis in a Young Adult With Down Syndrome. JCR Journal Of Clinical Rheumatology 2018, 24: 153-156. PMID: 29200025, DOI: 10.1097/rhu.0000000000000633.Peer-Reviewed Original ResearchAltmetricMeSH KeywordsAcute Kidney InjuryAdultAntibodies, Antineutrophil CytoplasmicBiopsyBlood TransfusionDiagnosis, DifferentialDown SyndromeGlucocorticoidsGranulomatosis with PolyangiitisHemoptysisHumansImmunoglobulins, IntravenousImmunologic FactorsKidneyMalePatient Care ManagementPatient SelectionRespiration, ArtificialRespiratory InsufficiencyRituximabTomography, X-Ray ComputedTreatment Outcome
2017
Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review
Bazan IS, Mensah KA, Rudkovskaia AA, Adonteng-Boateng PK, Herzog EL, Buckley L, Fares WH. Pulmonary arterial hypertension in the setting of scleroderma is different than in the setting of lupus: A review. Respiratory Medicine 2017, 134: 42-46. PMID: 29413506, DOI: 10.1016/j.rmed.2017.11.020.BooksCitationsAltmetricMeSH Keywords and ConceptsConceptsPulmonary arterial hypertensionConnective tissue disease-associated pulmonary arterial hypertensionConnective tissue diseasePulmonary hypertensionSSc-PAHArterial hypertensionSystemic sclerosisTissue diseaseElevated left ventricular filling pressurePathobiology of PAHLeft ventricular filling pressureMixed connective tissue diseasePre-capillary pulmonary hypertensionWorld Health Organization classificationSetting of lupusSetting of sclerodermaPulmonary vascular resistanceRight heart failureVentricular filling pressurePAH etiologyPathophysiologic criteriaSLE-PAHVascular resistanceProgressive diseaseSystemic lupusCyanosis of the foot.
Shi VJ, Leventhal JS, Mensah KA, Galan A, Choate KA. Cyanosis of the foot. Cutis 2017, 100: 206;209;210. PMID: 29136053.Peer-Reviewed Original ResearchCitations
2015
Lupus‐Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition
Mensah KA, Yadav R, Trow TK, Brunet CM, Fares WH. Lupus‐Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition. Case Reports In Medicine 2015, 2015: 328435. PMID: 26229536, PMCID: PMC4503546, DOI: 10.1155/2015/328435.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricConceptsPulmonary arterial hypertensionSystemic lupus erythematosusVariable courseRight-sided heart pressuresSevere pulmonary arterial hypertensionLife-threatening symptomsLong-term outcomesEvidence-based therapiesEffective treatment approachArterial hypertensionMultiorgan dysfunctionSLE flareHeart pressuresLupus erythematosusPrompt recognitionCirculatory shockSame patientTreatment approachesYoung womenLevel interventionsSymptomsSignificant improvementReportErythematosusHypertension
2014
Chapter 2. Diagnosis and Imaging of Insufficiency Fractures
Mensah KA and Schneider R. Insufficiency Fractures. Eds. Lane JM and Saleh A. Rosemont, IL: American Academy of Orthopaedic Surgeons, 2014.Peer-Reviewed Original Research
2013
Chapter 6. Basic Science of Immunology in Orthopaedics
Mensah KA and O’Keefe RJ. Orthopaedic Basic Science: Foundations of Clinical Practice, Fourth Edition. Eds. O'Keefe RJ, Jacobs JJ, Chu CR, and Einhorn TA. Rosemont, IL: American Academy of Orthopaedic Surgeons, 2013.Peer-Reviewed Original ResearchAtypical Femoral Fractures
Unnanuntana A, Saleh A, Mensah KA, Kleimeyer JP, Lane JM. Atypical Femoral Fractures. Journal Of Bone And Joint Surgery 2013, 95: e8. PMID: 23324969, DOI: 10.2106/jbjs.l.00568.Peer-Reviewed Original ResearchCitations
2011
Regulation of human osteoclast development by dendritic cell‐specific transmembrane protein (DC‐STAMP)
Chiu Y, Mensah KA, Schwarz EM, Ju Y, Takahata M, Feng C, McMahon LA, Hicks DG, Panepento B, Keng PC, Ritchlin CT. Regulation of human osteoclast development by dendritic cell‐specific transmembrane protein (DC‐STAMP). Journal Of Bone And Mineral Research 2011, 27: 79-92. PMID: 21987375, PMCID: PMC3304467, DOI: 10.1002/jbmr.531.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDendritic cell-specific transmembrane proteinImmunoreceptor tyrosine-based inhibitory motifOC precursorsInflammatory arthritisTransmembrane proteinSH2 domain-containing tyrosine phosphataseTransmembrane receptor-like proteinErosive inflammatory arthritisCell fusionTumor giant cellsMetabolic bone diseaseReceptor-like proteinDC-STAMP expressionTyrosine-based inhibitory motifCell surface receptorsBone diseaseHuman PBMCsTyrosine phosphataseOsteoclast developmentCytoplasmic tailGiant cellsCellular transformationOC formationOsteoclastogenesisSHP-1
2010
Mediation of nonerosive arthritis in a mouse model of lupus by interferon‐α–stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis
Mensah KA, Mathian A, Ma L, Xing L, Ritchlin CT, Schwarz EM. Mediation of nonerosive arthritis in a mouse model of lupus by interferon‐α–stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. Arthritis & Rheumatism 2010, 62: 1127-1137. PMID: 20131244, PMCID: PMC2854832, DOI: 10.1002/art.27312.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMyeloid dendritic cellsSystemic lupus erythematosusSerum-induced arthritisNZB xBone erosionDendritic cellsOsteoclast precursorsAntibody titersMouse modelAnti-dsDNA antibody titersDNA antibody titersMicrofocal computed tomographyCytokine interferon-alphaEffects of IFNalphaJaccoud's arthritisNonerosive arthritisSLE diseaseJoint inflammationLupus erythematosusAutoimmune diseasesNZW miceSerum administrationInterferon alphaFocal erosionsSLE monocytes
Academic Achievements & Community Involvement
activity American Physician Scientists Association
Professional OrganizationsBoard MemberDetailsBoard of Directors04/30/2014 - Presentactivity Yale Internal Medicine Residency Program
CommitteesMemberDetailsExecutive Council Member09/01/2013 - 06/29/2015honor Alpha Omega Alpha Honor Medical Society
International AwardAlpha Omega AlphaDetails02/28/2011United Statesactivity REF Marshall J. Schiff Memorial Lectureship in Inflammation and Joint Replacement: The Surface Expression Level of DC-STAMP Defines the Fusogenic Potential of Osteoclast Precursors (OCP): RANKL-Induced DC-STAMPlo OCP Are the Master-Fusogens
LectureAmerican College of Rheumatology Scientific MeetingDetails10/18/2009 - 10/18/2009Philadelphia, PA, United StatesAbstract/SynopsisOsteoclasts (OC) form by fusion of heterogeneous OC precursors (OCP). As OCP heterogeneity can be phenotyped by fusogenic potential (multinucleated master fusogens vs. mononuclear OCP donors) we hypothesized that DC-STAMP, a 7-transmembrane protein receptor required for OCP fusion, mediates this heterogeneity. To test this we evaluated the expression of fusogenic genes and the fusogenic potential of DC-STAMPhi vs. DC-STAMPlo OCP after culture with RANKL. We also evaluated DC-STAMP as an OCP biomarker in patients with inflammatory-erosive psoriatic arthritis (PsA). Although the DC-STAMP ligand remains unknown, this RANKL-induced factor delivers a critical signal to DC-STAMPhi mononuclear OCP, which induces the expression of genes involved in cell fusion while down-regulating DC-STAMP surface expression. The resulting DC-STAMPlo OCP are “master fusogens” that express higher levels of OC markers and pseudopods that seek out and attach to DC-STAMPhi OCP to form multinucleated OC. The higher frequency of DC-STAMP+ cells among PsA patients versus healthy controls suggests that DC-STAMP surface expression on PBMC, prior to RANKL exposure, may be a dynamic biomarker to assess the aggressiveness of erosive arthritis.
honor Melville A. Hare Distinction in Research Award for PhD thesis in Microbiology and Immunology
Yale School of Medicine AwardUniversity of Rochester School of Medicine and DentistryDetails01/01/2009United States
News
News
- October 09, 2018
Kudos
- November 06, 2017
Rheumatology Section News - November 2017